| [1] |
World Health Organization. Global Influenza Strategy2019-2030[EB/OL].
|
| [2] |
Hedberg P, Johansson N, Ternhag A, et al. Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus[J]. BMC Infect Dis,2022,22(1):108.
|
| [3] |
Liu YN, Zhang YF, Xu Q, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study[J]. Lancet Microbe,2023,4(5):e330-e339.
|
| [4] |
Arranz-Herrero J, Presa J, Rius-Rocabert S, et al. Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis[J]. Int J Infect Dis,2023,131(6):173-179.
|
| [5] |
Debes S, Haug JB, De Blasio BF, et al. Antibiotic consumption in a cohort of hospitalized adults with viral respiratory tract infection[J]. Antibiotics (Basel),2023,12(4):788.
|
| [6] |
中华人民共和国国家卫生健康委员会, 国家中医药管理局. 流行性感冒诊疗方案(2025年版)[J]. 中华临床感染病杂志(中英文),2025,18(1):1-5, 62.
|
| [7] |
中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志,2016,39(4):253-279.
|
| [8] |
尚红, 王毓三, 申子瑜. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社.
|
| [9] |
Yan G, Hu Z, Peng Y, et al. Exposure to bacterial lipopolysaccharide aggravates H1N1-mediated lung immunopathology via neutrophil extracellular trap formation[J]. Sci Rep,2025,15(1):40541.
|
| [10] |
中华人民共和国卫生部. 抗菌药物临床应用管理办法[J]. 中华临床感染病杂志,2012,5(4):193-196.
|
| [11] |
国家卫生健康委员会. 医院感染病例判定标准: 通用原则WS/T 857-2025[J]. 中国感染控制杂志,2025,24(8):1175-1177.
|
| [12] |
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis,2016,63(5):e61-e111.
|
| [13] |
Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review[J]. Intensive Care Med,2020,46(5):888-906.
|
| [14] |
Beliavsky A, Johnston B, Li Q, et al. Secondary infections in critically ill patients with viral pneumonia due to COVID-19 and influenza: a historical cohort study[J]. Can J Anaesth,2023,70(3):374-383.
|
| [15] |
Manohar P, Loh B, Nachimuthu R, et al. Secondary bacterial infections in patients with viral pneumonia[J]. Front Med (Lausanne),2020,7:420.
|
| [16] |
郭燕, 胡付品, 朱德妹, 等. 2023年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志,2024,24(6):627-637.
|
| [17] |
Teerawattanapong N, Kengkla K, Dilokthornsakul P, et al. Prevention and control of multidrug-resistant Gram-negative bacteria in adult intensive care units: A systematic review and network Meta-analysis[J]. Clin Infect Dis,2017,64(Suppl 2):S51-S60.
|
| [18] |
Sati H, Carrara E, Savoldi A, et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance[J]. Lancet Infect Dis,2025,25(9):1033-1043.
|
| [19] |
Reyes J, Komarow L, Chen L, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study[J]. Lancet Microbe,2023,4(3):e159-e170.
|
| [20] |
Lei TY, Liao BB, Yang LR, et al. Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat[J]. Microbiol Res,2024,288:127839.
|
| [21] |
曾玫, 夏君, 宗志勇, 等. 碳青霉烯类耐药革兰阴性菌感染的诊断, 治疗及防控指南[J]. 中国感染与化疗杂志,2024,24(2):135-151.
|
| [22] |
Won EJ, Park K, Jeong YS, et al. Evolution of bla (KPC) under the pressure of Carbapenems and Ceftazidime/Avibactam in a patient with persistent bacteremia caused by Klebsiella pneumoniae[J]. J Korean Med Sci,2024,39(25):e208.
|
| [23] |
Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update[J]. Infect Control Hosp Epidemiol,2022,43(6):687-713.
|
| [24] |
Pimenta LKL, Rodrigues CA, Filho ARG, et al. Staphylococcus spp. causatives of infections and carrier of blaZ, femA, and mecA genes associated with resistance[J]. Antibiotics (Basel),2023,12(4):671.
|
| [25] |
Diao H, Lu G, Zhang Y, et al. Risk factors for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infection of patients admitted in intensive care unit: a systematic review and meta-analysis[J]. J Hosp Infect,2024,149:77-87.
|
| [26] |
Paudel R, Shrestha E, Chapagain B, et al. Carbapenemase producing Gram negative bacteria: Review of resistance and detection methods[J]. Diagn Microbiol Infect Dis,2024,110(1):116370.
|
| [27] |
Slutsky A S, Ranieri V M. Ventilator-induced lung injury[J]. N Engl J Med,2013,369(22):2126-2136.
|
| [28] |
中华人民共和国国家卫生健康委员会. 呼吸机相关肺炎预防与控制标准[EB/OL]. 2025. WS/T 863-2025.
|
| [29] |
Sencio V, Machado MG, Trottein F. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes[J]. Mucosal Immunol,2021,14(2):296-304.
|
| [30] |
Mohammadshahi J, Ghobadi H, Shargi A, et al. Neutrophil-to-lymphocyte and platelet ratio (N/LP ratio), a reliable criterion for predicting in-hospital mortality in both genders infected with SARS-CoV-2[J]. Mediators Inflamm,2024,2024:5720709.
|
| [31] |
Schuetz P. How to best use procalcitonin to diagnose infections and manage antibiotic treatment[J]. Clin Chem Lab Med,2023,61(5):822-828.
|
| [32] |
Su W, Ju L, Hua Q, et al. Values of combined C-reactive protein, procalcitonin and serum amyloid A in differential diagnosis of bacterial and non-bacterial community acquired pneumonia in children[J]. Diagn Microbiol Infect Dis,2023,105(2):115865.
|